

DAFTAR PUSTAKA

- Ahmed, M. O., Elramalli, A. K., Amri, S. G., Abuzweda, A. R., & Abouzeed, Y. M. 2012. Isolation and screening of methicillin-resistant *Staphylococcus aureus* from health care workers in Libyan hospitals. *Eastern Mediterranean Health Journal*, 18(1), 37.
- Allin KH, Nielsen T, Pedersen O. 2015. Gut microbiota in patients with type 2 diabetes mellitus. *European Journal of Endocrinology*; 167-177.
- Aparna MS, Yadav S. 2008. Biofilms: microbes and disease. *Braz J Infect Dis*;12(6):526-30.
- Archer NK., Mazaitis MJ, Costerton JW, Leid JG., Powers ME, Shirtliff ME. 2011. *Staphylococcus aureus* biofilms: properties, regulation, and roles in human disease. *Virulence*; 2(5), 445-459.
- Biantoro IK. 2008. Methicillin-resistant *Staphylococcus aureus* (MRSA). Yogyakarta : Fakultas Kedokteran Universitas Gadjah Mada.
- Boles BR, Horswill AR. 2011. Staphylococcal biofilm disassembly. *Trends Microbiol*; 19: 449–455.
- Brooks GF. 2013. Jawetz, Melnick, & Adelberg's Medical Microbiology. 26ed. McGraw- Hill Medical.
- Brown AF, Leech JM, Rogers TR, and McLoughlin RM. 2014. *Staphylococcus aureus* colonization: modulation of host immune response and impact on human vaccine design,” *Frontiers in Immunology*; 4: 1–20.
- Buntaran L, Hatta M, Sultan AR, Dwiyantri R, Sabir M. 2013. Scmec type II gene is common among clinical isolates of methicillin-resistant *Staphylococcus aureus* in Jakarta, Indonesia. *BMC Res Notes*; 6: 110.
- Centers for Disease Control and Prevention. 2017. *Staphylococcus aureus* in Healthcare Settings. [online] Available at: <https://www.cdc.gov/hai/organisms/staph.html>.
- CharanKaur D, Khare AS. 2013. Biofilm formation and antibiotic susceptibility pattern in MRSA strains in a tertiary care rural hospital. *IJAR*; 3(1): 37–44. 34.
- Croes S, Deurenberg RH, Boumans ML, Beisser PS, Neef C, Stobberingh EE. 2009. *Staphylococcus aureus* biofilm formation at the physiologic glucose concentration depends on the *S. aureus* lineage. *BMC Microbiol*; 9: 229.

- Davies D. 2003. Understanding biofilm resistance to antibacterial agents. *Nature Reviews Drug Discovery*; 2(2): 114– 122.
- Dengler V, Foulston L, DeFrancesco AS, Losick R. 2015. An electrostatic net model for the role of extracellular DNA in biofilm formation by *Staphylococcus aureus*. *J. Bacteriol*; 197: 3779–3787.
- Donlan, R. M., & Costerton, J. W. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. *Clinical microbiology reviews*; 15(2): 167-193.
- Flemming HC, Wingender J. 2010. The biofilm matrix. *Nat Rev Microbiol*; 8(9): 623-33.
- Foulston L, Elsholz AKW, DeFrancesco AS, Losick R. 2014. The extracellular matrix of *Staphylococcus aureus* biofilms comprises cytoplasmic proteins that associate with the cell surface in response to decreasing pH. *MBio*; 5: e01667-14.
- Gordon RJ, Lowy FD. 2008. Pathogenesis of methicillin-resistant *Staphylococcus aureus* infection. *Clinical Infectious Diseases*; 46(5): S350–S359.
- Gunardi, W. D. 2014. Peranan Biofilm dalam Kaitannya dengan Penyakit Infeksi. *Jurnal Kedokteran Meditek*, 15(39A).
- Hanssen AM, Ericson Sollid JU. 2006. SCCmec in staphylococci: genes on the move. *FEMS Immunol Med Microbiol*;46(1):8–20.
- Hassan A, Usman J, Kaleem F, Omair M, Khalid A, Iqbal M. 2011. Detection and antibiotic susceptibility pattern of biofilm producing Gram positive and Gram negative bacteria isolated from a tertiary care hospital of Pakistan. *Malays J Microbiol*; 7(1):5 7–60. 33.
- Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. 2010. Reduced vancomycin susceptibility in *Staphylococcus aureus*, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. *Clin Microbiol Rev*; 23(1): 99–139.
- Jamal M, Tasneem U, Hussain T, Saadia Andleeb S. 2015. Bacterial Biofilm: Its Composition, Formation and Role in Human Infections. *Research & Reviews: Journal of Microbiology and Biotechnology*. RRJMB; 4(3).
- Jawetz, M. 2007. *Adelberg's Medical microbiology. Antibacterial and Antifungal chemotherapy* (Prentice-Hall International Inc).

- Kamath MP, Shenoy V, Mittal N, Sharma N. 2013. Microbiological analysis of paranasal sinuses in chronic sinusitis—A south Indian coastal study. *Egyptian Journal of Ear, Nose, Throat and Allied Sciences*; 14(3): 185-189.
- Kim JH, Kim CH, Hacker J, Ziebuhr W, Lee BK, Cho SH. 2008. Molecular characterization of regulatory genes associated with biofilm variation in a *Staphylococcus aureus* strain. *Journal of Microbiology Biotechnology*; 18(1): 28–34.
- Kock R, Becker K, Cookson B et al. 2010. Methicillin-resistant *Staphylococcus aureus* (MRSA): burden of disease and control challenges in Europe. *Eurosurveillance*; 15(41): 19694-19688.
- Kostakioti M, Hadjifrangiskou M, Hultgren SJ. 2013. Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era. *Cold Spring Harb Perspect Med*; 3(4): a010306.
- Kuo SC, Chiang MC, Lee WS, Chen LY, Wu HS, Yu KW, Fung CP, Wang FD. 2012. Comparison of microbiological and clinical characteristics based on SCCmec typing in patients with community-onset methicillin-resistant *Staphylococcus aureus* (MRSA) bacteraemia. *Int J Antimicrob Agents*; 39(1): 22–26.
- Lade H, Park JH, Chung SH, Kim IH, Kim J-M, Joo H-S, Kim J-S. 2019. Biofilm Formation by *Staphylococcus aureus* Clinical Isolates is Differentially Affected by Glucose and Sodium Chloride Supplemented Culture Media. *Journal of Clinical Medicine*; 8(11): 1853.
- Lambadi PR, Sharma TK, Kumar P, Vasnani P, Thalluri SM, Bisht N, Pathania R, Navani NK. 2015. Facile biofunctionalization of silver nanoparticles for enhanced antibacterial properties, endotoxin removal, and biofilm control. *Int J Nanomedicine*; 10: 2155–2171.
- Loresta S, Murwani S, Trisunuwati P. 2012. Efek Ekstrak Etanol daun kelor (*Moringa Oleifera*) Terhadap Pembentukan Biofilm *Staphylococcus aureus* Secara In Vitro.
- Melzer M, Welch C. 2013. Thirty-day mortality in UK patients with community-onset and hospital-acquired methicillin susceptible *Staphylococcus aureus* bacteraemia. *Journal of Hospital Infection*; 84(2): 143–150.
- Neopane P, Nepal HP, Shrestha R, Uehara O, Abiko Y. 2018. In vitro biofilm formation by *Staphylococcus aureus* isolated from wounds of hospital-

- admitted patients and their association with antimicrobial resistance. *Int J Gen Med*; 11:2 5-32.
- Ness T. 2010. Multiresistant bacteria in ophthalmology. *Ophthalmology*; 107(4): 318–322.
- Neyra RC, Frisancho JA, Rinsky JL et al. Multidrugresistant and methicillin-resistant *Staphylococcus aureus* (MRSA) in hog slaughter and processing plant workers and their community in North Carolina (USA). *Environmental Health Perspectives*; 22(5): 471–477.
- Nuryastuti T, van der Mei HC, Busscher HJ, Irvati S, Aman AT, Krom BP. 2009. Effect of cinnamon oil on *icaA* expression and biofilm formation by *Staphylococcus epidermidis*. *Applied and environmental microbiology*, 75(21), 6850-6855.
- Ohadian Moghadam S, Pourmand MR, Aminharati F. 2014. Biofilm formation and antimicrobial resistance in Methicillin-Resistant *Staphylococcus aureus* isolated from burn patients, Iran. *The Journal of Infection in Developing Countries*; 8(12): 1511-1517.
- Olson ME, King JM, Yahr TL, Horswill AR. 2013. Sialic acid catabolism in *Staphylococcus aureus*. *J. Bacteriol*; 195: 1779–1788.
- Piechota M, Kot B, Frankowska-Maciejewska A, Gruzewska A, Woźniak-Kosek A. 2018. Biofilm Formation by Methicillin-Resistant and Methicillin-Sensitive *Staphylococcus aureus* Strains from Hospitalized Patients in Poland. *Biomed Res Int*; 27(2018): 4657396.
- Pratiwi SUT, Lagemdijk EL, de Weert S, Idroes R, Hertiani T, Van den Hondel C. 2015. Effect of *Cinnamum burmannii* Nees ex Bl. and *Massoia* aromatic Becc. Essential oil on Planctonic Growth and Biofilm formation of *Pseudomonas aeruginosa* and *Staphylococcus aureus* In Vitro. *International Journal of Applied Research in Natural Product*; 8(2): 1-13.
- Regassa LB, Novick RP, Betley MJ. 1992. Glucose and nonmaintained pH decrease expression of the accessory gene regulator (*agr*) in *Staphylococcus aureus*. *Infect. Immun*; 60: 3381–3388.
- Sastoaningsih D. 2018. Prevalence and characterization of *Staphylococcus aureus* causing community-acquired skin and soft tissue infections on Java and Bali, Indonesia. *Pubmed*.

- Simoes M, Bennett RN, and Rosa EAS. 2009. Understanding antimicrobial activities of phytochemicals against multidrug resistant bacteria and biofilms. *Natural Product Reports*; 26(6): 746–757.
- Soleha TU, Apriliana E, Hardita WU. 2017. Perbedaan Jumlah Flora Normal Rongga Mulut pada Usia Lanjut dan Dewasa yang pernah Menerima Pengobatan Antibiotik di Bandar Lampung. *Medula*.
- Stewart PS and Costerton JW. 2001. Antibiotic resistance of bacteria in biofilms. *The Lancet*; 358(9276): 135–138.
- Sugimoto S, Sato F, Miyakawa R, et al. 2018. Broad impact of extracellular DNA on biofilm formation by clinically isolated Methicillin-resistant and -sensitive strains of *Staphylococcus aureus*. *Sci Rep*; 8: 2254.
- Sultan AR, Lattwein KR, Toom NAL, et al. 2021. Paracetamol modulates biofilm formation in *Staphylococcus aureus* clonal complex 8 strains. *Scientific Reports*; 11(1):5114.
- Sultan AR, Tavakol M, Lemmens-den Toom NA, Croughs PD, Verkaik NJ, Verbon A, van Wamel WJB. 2022. Real time monitoring of *Staphylococcus aureus* biofilm sensitivity towards antibiotics with isothermal microcalorimetry. *PLoS One*; 17(2): e0260272.
- Taglialegna A, Navarro S, Ventura S, Garnett JA, Matthews S, Penades JR, Lasa I, Valle J. 2016. Staphylococcal bap proteins build amyloid scaffold biofilm matrices in response to environmental signals. *PLoS Pathog*; 12: e1005711.
- Wu WS, Chen CC, Chuang YC, et al. 2013. Efficacy of combination oral antimicrobial agents against biofilm-embedded methicillin-resistant *Staphylococcus aureus*. *J Microbiol Immunol Infect*; 46(2): 89–95.

LAMPIRAN

1. Lampiran Persetujuan Etik



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 415/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 15 Agustus 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22060257		No Sponsor	
Peneliti Utama	dr. Priady Wira P		Protokol	
Judul Peneliti	Gambaran Massa Biofilm pada Isolat Bakteri Methicillin-Susceptible Staphylococcus aureus dan Methicillin-Resistant Staphylococcus aureus di Rumah Sakit Pendidikan Universitas Hasanuddin			
No Versi Protokol	2	Tanggal Versi	8 Agustus 2022	
No Versi PSP		Tanggal Versi		
Tempat Penelitian	RS Universitas Hasanuddin Makassar			
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal		Masa Berlaku	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)		15 Agustus 2022 sampai 15 Agustus 2023	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)		Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amademen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan